Physician profile
Robert L Walker
NPI 1649216680
$5,273.71
in general payments reported to CMS, 2019-2025
30 companies · $442 in 2025
The $442 reported for 2025 was more than what 92% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $910 · 2021: $911 · 2022: $646 · 2023: $632 · 2024: $642 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $686.28 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $607.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $602.29 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $537.27 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $513.90 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $319.12 | 2019-2025 | Mounjaro, Zepbound |
| Global Blood Therapeutics, INC. | $286.03 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.80 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $257.17 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Mylan Specialty L.P. | $199.66 | 2022-2024 | Yupelri |
| Abbvie INC. | $159.73 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $117.24 | 2024-2025 | Gemtesa |
| Astellas Pharma US INC | $107.45 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $97.35 | 2019-2022 | |
| Lundbeck LLC | $70.51 | 2024-2025 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $65.10 | 2022 | |
| Abbott Laboratories | $54.78 | 2021-2024 | Proclaim, Freestyle Libre |
| Allergan, INC. | $39.21 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.14 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $38.70 | 2023 | Rexulti |
| Dexcom, INC. | $33.61 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $26.34 | 2022 | |
| Siemens Medical Solutions USA, INC. | $24.77 | 2020 | |
| Amgen INC. | $22.93 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.13 | 2025 | Caplyta |
| Evoke Pharma, INC. | $15.23 | 2020 | |
| Avanir Pharmaceuticals, INC. | $14.85 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.97 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.31 | 2019 | |
| Boston Scientific Corporation | $12.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.